{
    "ticker": "ONCR",
    "name": "Oncorus, Inc.",
    "description": "Oncorus, Inc. is an innovative biotechnology company focused on developing transformative immunotherapies for cancer patients. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus aims to harness the power of oncolytic viruses to stimulate the immune system and attack tumors. The company's proprietary platform technology enables the engineering of oncolytic viruses to enhance their effectiveness and safety, offering a new approach to cancer treatment. Oncorus is actively advancing its lead product candidate, ONCR-177, a novel immunotherapy designed to treat patients with solid tumors. The company is committed to addressing the significant unmet needs in oncology by developing therapies that can improve response rates and survival outcomes. Oncorus collaborates with leading academic institutions and industry partners to further its research and development efforts. With a dedicated team of scientists and industry veterans, Oncorus is positioned to make significant contributions to the field of cancer immunotherapy and improve the lives of patients facing cancer.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.oncorus.com",
    "ceo": "William D. McGowan",
    "social_media": {
        "twitter": "https://twitter.com/Oncorus",
        "linkedin": "https://www.linkedin.com/company/oncorus/"
    },
    "investor_relations": "https://investors.oncorus.com",
    "key_executives": [
        {
            "name": "William D. McGowan",
            "position": "CEO"
        },
        {
            "name": "David M. McNally",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapies",
            "products": [
                "ONCR-177"
            ]
        }
    ],
    "seo": {
        "meta_title": "Oncorus, Inc. | Innovative Cancer Immunotherapies",
        "meta_description": "Oncorus, Inc. is a biotechnology company dedicated to developing transformative immunotherapies for cancer treatment. Learn about our innovative approaches and pipeline.",
        "keywords": [
            "Oncorus",
            "Immunotherapy",
            "Cancer Treatment",
            "Oncolytic Viruses",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Oncorus known for?",
            "answer": "Oncorus is known for developing innovative immunotherapies using oncolytic viruses to treat cancer."
        },
        {
            "question": "Who is the CEO of Oncorus?",
            "answer": "William D. McGowan is the CEO of Oncorus, Inc."
        },
        {
            "question": "Where is Oncorus headquartered?",
            "answer": "Oncorus is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Oncorus's lead product candidate?",
            "answer": "Oncorus's lead product candidate is ONCR-177, designed to treat solid tumors."
        },
        {
            "question": "When was Oncorus founded?",
            "answer": "Oncorus was founded in 2015."
        }
    ],
    "competitors": [
        "MRNA",
        "NVAX",
        "PSTV",
        "CLDX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "MRK",
        "BMY"
    ]
}